dc.contributor.author | Kaya, E. | |
dc.contributor.author | Kibar, Y. | |
dc.contributor.author | Yilmaz, S. | |
dc.contributor.author | Ozcan, A. | |
dc.contributor.author | Kopru, B. | |
dc.contributor.author | Ebiloglu, T. | |
dc.contributor.author | Irkilata, H.C. | |
dc.date.accessioned | 2021-12-21T08:41:12Z | |
dc.date.available | 2021-12-21T08:41:12Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 19201214 | |
dc.identifier.uri | https://doi.org/10.5489/cuaj.4489 | |
dc.identifier.uri | http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1355 | |
dc.description.abstract | Introduction: We aimed to evaluate whether or not mitomycin-C (MMC) has an antifibrotic effect on transforming growth factor-beta (TGF-β)-induced Peyronie's disease (PD) in a rat model. Methods: Eighteen 12-week-old male Sprague-Dawley rats were divided i | |
dc.language.iso | English | |
dc.publisher | Canadian Urological Association | |
dc.rights | All Open Access, Bronze, Green | |
dc.title | The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model | |
dc.type | Article | |
dc.relation.journal | Canadian Urological Association Journal | |
dc.identifier.issue | 11 | |
dc.identifier.startpage | E441 | |
dc.identifier.endpage | E445 | |
dc.identifier.volume | 11 | |
dc.identifier.doi | 10.5489/cuaj.4489 | |
dc.relation.issue | 11 | |
dc.relation.volume | 11 | |